When levels decline due to age, stress, or illness, biological function suffers
Recent research has focused on the unique pharmacokinetics of linagliptin, specifically the high plasma protein binding and long half-life, which may be exploited for tailored dosing in various clinical conditions, including specific patient populations [22]
In 2025, several major studies began to connect GLP-1 therapy to healthier aging
Enhanced Confidence: Achieve a more youthful and vibrant appearance
If the patient has a bacterial infection, antibiotics should be added
A study, expected to be completed in August 2027, is underway to evaluate the safety of Wegovy exposure during pregnancy